Trial reportOphthalmology2019
Mycotic Antimicrobial Localized Injection: A Randomized Clinical Trial Evaluating Intrastromal Injection of Voriconazole.
Trial report in Ophthalmology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 54 citations in OpenAlex.
- Adjunctive povidone-iodine forAntimicrobial agents and chemotherapy · 2026Trial
- Sulfur Vacancy-Rich MoSAdvanced healthcare materials · 2026Article
- Evaluation of corneal intrastromal voriconazole injection as an adjuvant approach in recalcitrant fungal keratitis.Journal of ophthalmic inflammation and infection · 2026Article
- Latent Supervision: A Method for Improved Performance and Calibration of Machine Learning Classification Models in Ophthalmology.Ophthalmology science · 2026Article
- Adjunctive tacrolimus in the treatment of fungal keratitis requiring therapeutic penetrating keratoplasty.American journal of ophthalmology case reports · 2026Article
- Comprehensive insights into the role of nanocarriers in advancing azole-based ocular therapeutics.RSC advances · 2025Review
- Article
- Article
- Recent Advances in Diagnosis and Treatment Approaches in Fungal Keratitis: A Narrative Review.Microorganisms · 2024Review
- Fungal Keratitis: Diagnosis, Management, and Recent Advances.Clinical ophthalmology (Auckland, N.Z.) · 2024Review
- Intrastromal Injections in the Management of Infectious Keratitis.Pharmaceutics · 2023Review
- Clinical Observation of Low-Temperature Plasma Ablation Combined with Drug Therapy in the Treatment of Fungal Keratitis.Infection and drug resistance · 2023Article
- Management of Filamentous Fungal Keratitis: A Pragmatic Approach.Journal of fungi (Basel, Switzerland) · 2022Review
- The Case for Fungal Keratitis to Be Accepted as a Neglected Tropical Disease.Journal of fungi (Basel, Switzerland) · 2022Review
- Candida keratitis and endopthalmitis after corneal transplantation; two case reports, a novel regimen and literature overview of therapeutic options.European journal of ophthalmology · 2021Article
- Review
- Recent Perspectives in the Management of Fungal Keratitis.Journal of fungi (Basel, Switzerland) · 2021Review
- Intrastromal natamycin: A well-aimed arrow in a difficult battle.Indian journal of ophthalmology · 2021Article
- Comparison of modified corneal cross-linking with intrastromal voriconazole for the treatment of fungal corneal ulcer.Experimental and therapeutic medicine · 2021Article
- Voriconazole in the successful management of a case of Acanthamoeba-Cladosporium keratitis.American journal of ophthalmology case reports · 2021Article
Corrections and comments
- Commented on by
- Commented on byReply.2019
Authors and funding
9 authors at 2 institutions in 2 countries.
Funding
Abstract
purposeTo determine if there is a benefit to adjuvant intrastromal voriconazole (ISV) injections for primary treatment of filamentous fungal keratitis.
designOutcome-masked, randomized controlled clinical trial.
participantsPatients with moderate vision loss resulting from a smear-positive fungal ulcer.
methodsStudy eyes were randomized to topical natamycin plus ISV injection versus topical natamycin alone.
main outcome measuresThe primary outcome of the trial was microbiological cure on 3-day repeat culture analysis. Secondary outcomes included microbiological cure on 7-day repeat culture analysis; 3-week and 3-month best spectacle-corrected visual acuity; infiltrate or scar size or both; rate of perforation; therapeutic penetrating keratoplasty (TPK); and other adverse events.
resultsA total of 151 patients with smear-positive ulcers were screened and 70 were enrolled at Aravind Eye Hospital, Pondicherry, India. Baseline cultures grew Fusarium in 19 samples (27%), Aspergillus in 17 samples (24%), and other filamentous fungi in 19 samples (27%) and showed negative results in 13 samples (19%). Those randomized to ISV injection had 1.82 times the odds of 3-day culture positivity after controlling for baseline culture status (95% confidence interval [CI], 0.65-5.23; P = 0.26, bias-corrected logistic regression) and 1.98 times the odds of positive 7-day culture results, after controlling for baseline culture status (95% CI, 0.69-5.91; P = 0.20, bias-corrected logistic regression). Those randomized to ISV injection showed 0.5 logMAR lines (approximately 0.5 Snellen lines) of decreased visual acuity (95% CI, -2.6 to 3.6 lines; P = 0.75) and 0.55 mm worse infiltrate or scar size or both at 3 months after controlling for baseline values (95% CI, -0.13 to 1.25; P = 0.11). Intrastromal voriconazole injections showed a 2.85-fold increased hazard of perforation after controlling for baseline infiltrate depth (95% CI, 0.76-10.75; P = 0.12) but no difference in the rate of TPK (hazard ratio, 0.95; 95% CI, 0.44-2.04; P = 0.90).
conclusionsThere seems to be no benefit to adding ISV injections to topical natamycin in the primary treatment of moderate to severe filamentous fungal ulcers. Studies consistently suggest that voriconazole has a limited role in the treatment of filamentous fungal ulcers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.